In this week’s edition of InnovationRx, we look at cheaper biologic drugs, Novo Nordisk’s $2 billion next-gen obesity drug deal, new ways of fighting cancer, and more.
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in ...
The BRAFTOVI combination regimen is the only approved targeted regimen for first-line BRAF-V600E mutant metastatic colorectal cancerPivotal results from the Phase 3 portion with mFOLFOX6 of the ...
Pfizer shares fell 3.3% Tuesday on what some market watchers called underwhelming study results for an experimental weight-loss drug the drugmaker obtained after a contentious and costly bidding war ...
Trump launched TrumpRx, a new website offering discounted prescription medicines. See how to use it, which drugs are included ...
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, is scheduled to present and host investor meetings at the followin ...
BREAKWATER trial Cohort 3 analysis demonstrated statistically significant and clinically meaningful improvement in ...
The list price of Wegovy will be cut in half on January 1, 2027, plummeting from around $1,350 to $675 a month. The cost of ...
Pfizer announces positive results from pivotal BREAKWATER trial of Braftovi in combo with cetuximab & Folfiri in patients with metastatic colorectal cancer: New York Wednesday, Fe ...
The American pharmaceutical company Moderna announced that the United States Food and Drug Administration (FDA) has refused ...
GLP-1 drugs for weight loss are growing in popularity in the U.S. and across the world. Here's what some users say about their experiences with the medicines.
BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results